Neglected tropical diseases and infectious illnesses: potential targeted peptides employed as hits compounds in drug design

References

• World Health Organization (WHO). Neglected tropical diseases [cited 2019 Aug 22]. Available from: https://www.who.int/neglected_diseases/diseases/en/.
   Google Scholar
• Cook PP. What is new in infectious diseases? N C Med J. 2016;77(5):320–323.
   PubMedGoogle Scholar
• Engels D, Zhou XN. Neglected tropical diseases: an effective global response to local poverty-related disease priorities. Infect Dis Poverty. 2020;9(1):10.
   PubMed Web of Science ®Google Scholar
• Ferreira LG, Andricopulo AD. Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective. Drug Discov Today. 2016;21(10):1699–1710.
   PubMed Web of Science ®Google Scholar
• Ferreira LLG, Andricopulo AD. Drugs and vaccines in the 21st century for neglected diseases. Lancet Infect Dis. 2019;19(2):125–127.
   PubMed Web of Science ®Google Scholar
• Ortu G, Williams O. Neglected tropical diseases: exploring long term practical approaches to achieve sustainable disease elimination and beyond. Infect Dis Poverty. 2017;6(1):147.
   PubMedGoogle Scholar
• Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443–1467.
   PubMedGoogle Scholar
• Craik DJ, Fairlie DP, Liras S, et al. The future of peptide-based drugs. Chem. Biol. Drug Des. 2013;81(1):136–147.
   PubMed Web of Science ®Google Scholar
• Aungst B, Saitoh H, Burcham D, et al. Enhancement of the intestinal absorption of peptides and nonpeptides. J Control Release. 1996;41(1–2):19–31.
   Web of Science ®Google Scholar
• Torchilin V. Intracellular delivery of protein and peptide therapeutics. Drug Discov Today Technol. 2009;5(2–3):95–103.
   Google Scholar
• Boohaker RJ, Lee MW, Vishnubhotla P, et al. The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012;19(22):3794–3804.
   PubMed Web of Science ®Google Scholar
• Gilad Y, Firer M, Gellerman G. Recent innovations in peptide based targeted drug delivery to cancer cells. Biomedicines. 2016;4(2):11.
   PubMed Web of Science ®Google Scholar
• Pérez-Picaso L, Olivo HF, Argotte-Ramos R, et al. Linear and cyclic dipeptides with antimalarial activity. Bioorganic Med Chem Lett. 2012;22(23):7048–7051.
   PubMed Web of Science ®Google Scholar
• Recio C, Maione F, Iqba AJ, et al. The potential therapeutic application of peptides and peptidomimetics in cardiovascular disease. Front. Pharmacol. 2017;7:1–11.
   Web of Science ®Google Scholar
• Araste F, Abnous K, Hashemi M, et al. Peptide-based targeted therapeutics: focus on cancer treatment. J Control Release. 2018;292:141–162.
   PubMed Web of Science ®Google Scholar
• Hayashi MAF, Ducancel F, Konno K. Natural peptides with potential applications in drug development, diagnosis, and/or biotechnology. Int J Pept. 2012;2012:1–2.
   Google Scholar
• Rastogi S, Shukla S, Kalaivani M, et al. Peptide-based therapeutics: quality specifications, regulatory considerations, and prospects. Drug Discov Today. 2019;24(1):148–162.
   PubMed Web of Science ®Google Scholar
• Rafferty J, Nagaraj H, McCloskey AP, et al. Peptide therapeutics and the pharmaceutical industry: barriers encountered translating from the laboratory to patients. Curr Med Chem. 2016;23(37):4231–4259.
   PubMed Web of Science ®Google Scholar
• Clinical Trials.gov. ; 2020 [cited 2020 June 1]. Available from: https://clinicaltrials.gov/
   Google Scholar
• Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discov Today. 2015;20(1):122–128.
   PubMed Web of Science ®Google Scholar
• Kaspar AA, Reichert JM. Future directions for peptide therapeutics development. Drug Discov Today. 2013;18(17–18):807–817.
   PubMed Web of Science ®Google Scholar
• Pant S, Singh M, Ravichandiran V, et al. Peptide-like and small-molecule inhibitors against Covid-19. J Biomol Struct Dyn. 2020;6:1–10.
   Google Scholar
• Alhoot MA, Rathinam AK, Wang SM, et al. Inhibition of dengue virus entry into target cells using synthetic antiviral peptides. Int J Med Sci. 2013;10(6):719–729.
   PubMed Web of Science ®Google Scholar
• Panya A, Bangphoomi K, Choowongkomon K, et al. Peptide inhibitors against dengue virus infection. Chem Biol Drug Des. 2014;84(2):148–157.
   PubMed Web of Science ®Google Scholar
• Nitsche C, Behnam MA, Steuer C, et al. Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease. Antiviral Res. 2012;94(1):72–79.
   PubMed Web of Science ®Google Scholar
• Giroud M, Kuhn B, Saint-Auret S, et al. 2 H-1,2,3-triazole-based dipeptidyl nitriles: potent, selective, and trypanocidal rhodesain inhibitors by structure-based design. J Med Chem. 2018;61(8):3370–3388.
   PubMed Web of Science ®Google Scholar
• Royo S, Rodríguez S, Schirmeister T, et al. Dipeptidyl enoates as potent rhodesain inhibitors that display a dual mode of action. ChemMedChem. 2015;10(9):1484–1487.
   PubMed Web of Science ®Google Scholar
• Latorre A, Schirmeister T, Kesselring J, et al. Dipeptidyl nitroalkenes as potent reversible inhibitors of cysteine proteases rhodesain and cruzain. ACS Med Chem Lett. 2016;7(12):1073–1076.
   PubMed Web of Science ®Google Scholar
• Joyeau R, Maoulida C, Guillet C, et al. Synthesis and activity of pyrrolidinyl- and thiazolidinyl-dipeptide derivatives as inhibitors of the Tc80 prolyl oligopeptidase from Trypanosoma cruzi. Eur J Med Chem. 2000;35(2):257–266.
   PubMed Web of Science ®Google Scholar
• Konno K, Rangel M, Oliveira JS, et al. Decoralin, a novel linear cationic alpha-helical peptide from the venom of the solitary eumenine wasp Oreumenes decoratus. Peptides. 2007;28(12):2320–2327.
   PubMed Web of Science ®Google Scholar
• Rangel M, Cabrera MP, Kazuma K, et al. Chemical and biological characterization of four new linear cationic α-helical peptides from the venoms of two solitary eumenine wasps. Toxicon. 2011;57(7–8):1081–1092.
   PubMed Web of Science ®Google Scholar
• Kückelhaus SA, Leite JR, Muniz-Junqueira MI, et al. Antiplasmodial and antileishmanial activities of phylloseptin-1, an antimicrobial peptide from the skin secretion of Phyllomedusa azurea (Amphibia). Exp Parasitol. 2009;123(1):11–16.
   PubMed Web of Science ®Google Scholar
• Mangoni ML, Papo N, Saugar JM, et al. Effect of natural L- to D-amino acid conversion on the organization, membrane binding, and biological function of the antimicrobial peptides bombinins H. Biochemistry. 2006;45(13):4266–4276.
   PubMed Web of Science ®Google Scholar
• Mangoni ML, Saugar JM, Dellisanti M, et al. Temporins, small antimicrobial peptides with leishmanicidal activity. J Biol Chem. 2005;280(2):984–990.
   PubMed Web of Science ®Google Scholar
• Alente C, Guedes RC, Moreira R, et al. Dipeptide vinyl sultams: synthesis via the Wittig-Horner reaction and activity against papain, falcipain-2 and Plasmodium falciparum. Bioorg Med Chem Lett. 2006;16(15):4115–4119.
   PubMed Web of Science ®Google Scholar
• Capela R, Oliveira R, Gonçalves LM, et al. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg Med Chem Lett. 2009;19(12):3229–3232.
   PubMed Web of Science ®Google Scholar
• Mallik SK, Li DY, Cui M, et al. Synthesis and evaluation of peptidyl α,β-unsaturated carbonyl derivatives as anti-malarial calpain inhibitors. Arch Pharm Res. 2012;35(3):469–479.
   PubMed Web of Science ®Google Scholar
• Skinner-Adams TS, Lowther J, Teuscher F, et al. Identification of phosphinate dipeptide analog inhibitors directed against the Plasmodium falciparum M17 leucine aminopeptidase as lead antimalarial compounds. J Med Chem. 2007;50(24):6024–6031.
   PubMed Web of Science ®Google Scholar
• Harris KS, Casey JL, Coley AM, et al. Rapid optimization of a peptide inhibitor of malaria parasite invasion by comprehensive N-methyl scanning. J Biol Chem. 2009;284(14):9361–9371.
   PubMed Web of Science ®Google Scholar
• Silva AF, Torres MT, Silva LS, et al. Angiotensin II-derived constrained peptides with antiplasmodial activity and suppressed vasoconstriction. Sci Rep. 2017;7(1):14326.
   PubMedGoogle Scholar
• Torrent M, Pulido D, Rivas L, et al. Antimicrobial peptide action on parasites. Curr Drug Targets. 2012;13(9):1138–1147.
   PubMed Web of Science ®Google Scholar
• Kumar M, Vijayakrishnan R, Subba Rao G. In silico structure-based design of a novel class of potent and selective small peptide inhibitor of Mycobacterium tuberculosis Dihydrofolate reductase, a potential target for anti-TB drug discovery. Mol Divers. 2010;14(3):595–604.
   PubMed Web of Science ®Google Scholar
• Kavanagh ME, Gray JL, Gilbert SH, et al. Substrate fragmentation for the design of M. tuberculosis CYP121 inhibitors. ChemMedChem. 2016;11(17):1924–1935.
   PubMed Web of Science ®Google Scholar
• McLean KJ, Carroll P, Lewis DG, et al. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J Biol Chem. 2008;283(48):33406–33416.
   PubMed Web of Science ®Google Scholar
• McLean KJ, Cheesman MR, Rivers SL, et al. Expression, purification and spectroscopic characterization of the cytochrome P450 CYP121 from Mycobacterium tuberculosis. J Inorg Biochem. 2002;91(4):527–541.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv. FEMS Microbiol Lett. 2005;251(1):19–22.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis. FEMS Microbiol Lett. 2006;261(2):181–186.
   PubMed Web of Science ®Google Scholar
• Ahmad Z, Sharma S, Khuller GK. The potential of azole antifungals against latent/persistent tuberculosis. FEMS Microbiol Lett. 2006;258(2):200–203.
   PubMed Web of Science ®Google Scholar
• Kumar NS, Mohandas C. Antimycobacterial activity of cyclic dipeptides isolated from Bacillus sp. N strain associated with entomopathogenic nematode. Pharm Biol. 2014;52(1):91–96.
   PubMed Web of Science ®Google Scholar
• Krasnov VP, Vigorov AY, Musiyak VV, Nizova IA, et al. Synthesis and antimycobacterial activity of N-(2-aminopurin-6-yl) and N-(purin-6-yl) amino acids and dipeptides. Bioorg Med Chem Lett. 2016;26(11):2645–2648.
   PubMed Web of Science ®Google Scholar
• Chen L, Liu Y, Wang S, et al. Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses. Antiviral Res. 2017;141:140–149.
   PubMed Web of Science ®Google Scholar
• Li Y, Zhang Z, Phoo WW, et al. Structural dynamics of Zika virus NS2B-NS3 protease binding to dipeptide inhibitors. Structure. 2017;25(8):1242–1250.e3.
   PubMed Web of Science ®Google Scholar
• Dighe SN, Ekwudu O, Dua K, et al. Recent update on anti-dengue drug discovery. Eur J Med Chem. 2019;176:431–455.
   PubMed Web of Science ®Google Scholar
• Lim SP. Dengue drug discovery: progress, challenges and outlook. Antiviral Res. 2019;163:156–178.
   PubMed Web of Science ®Google Scholar
• Low JG, Ooi EE, Vasudevan SG. Current status of dengue therapeutics research and development. J Infect Dis. 2017;215(suppl_2):S96–S102.
   PubMedGoogle Scholar
• Villalta F, Rachakonda G. Advances in preclinical approaches to Chagas disease drug discovery. Expert Opin Drug Discov. 2019;14(11):1161–1174.
   PubMed Web of Science ®Google Scholar
• Cazzulo JJ, Cazzulo Franke MC, Martínez J, et al. Some kinetic properties of a cysteine proteinase (cruzipain) from Trypanosoma cruzi. Biochim Biophys Acta. 1990;1037(2):186–191.
   PubMed Web of Science ®Google Scholar
• Harth G, Andrews N, Mills AA, et al. Peptide-fluoromethyl ketones arrest intracellular replication and intercellular transmission of Trypanosoma cruzi. Mol Biochem Parasitol. 1993;58(1):17–24.
   PubMed Web of Science ®Google Scholar
• Chung MC, Gonçalves MF, Colli W, et al. Synthesis and in vitro evaluation of potential antichagasic dipeptide prodrugs of primaquine. J Pharm Sci. 1997;86(10):1127–1131.
   PubMed Web of Science ®Google Scholar
• Kaur K, Jain M, Khan SI, et al. Amino acid, dipeptide and pseudodipeptide conjugates of ring-substituted 8-aminoquinolines: synthesis and evaluation of anti-infective, β-haematin inhibition and cytotoxic activities. Eur J Med Chem. 2012;52:230–241.
   PubMed Web of Science ®Google Scholar
• Pérez-Cordero JJ, Lozano JM, Cortés J, et al. Leishmanicidal activity of synthetic antimicrobial peptides in an infection model with human dendritic cells. Peptides. 2011;32(4):683–690.
   PubMed Web of Science ®Google Scholar
• Savoia D, Guerrini R, Marzola E, et al. Synthesis and antimicrobial activity of dermaseptin S1 analogues. Bioorg Med Chem. 2008;16(17):8205–8209.
   PubMed Web of Science ®Google Scholar
• Mangoni ML. Temporins, anti-infective peptides with expanding properties. Cell Mol Life Sci. 2006;63(9):1060–1069.
   PubMed Web of Science ®Google Scholar
• Lynn MA, Kindrachuk J, Marr AK, Jenssen H, et al. Effect of BMAP-28 antimicrobial peptides on Leishmania major promastigote and amastigote growth: role of leishmanolysin in parasite survival. PLoS Negl Trop Dis. 2011;5(5):e1141
   PubMed Web of Science ®Google Scholar
• Löfgren SE, Miletti LC, Steindel M, et al. Trypanocidal and leishmanicidal activities of different antimicrobial peptides (AMPs) isolated from aquatic animals. Exp Parasitol. 2008;118(2):197–202.
   PubMed Web of Science ®Google Scholar
• Guerrero E, Saugar JM, Matsuzaki K, et al. Role of positional hydrophobicity in the leishmanicidal activity of magainin 2. Antimicrob Agents Chemother. 2004;48(8):2980–2986.
   PubMed Web of Science ®Google Scholar
• Lozano JM, Cuadrado BS, Delgado G, et al. Cationic peptides harboring antibiotic capacity are selective for Leishmania panamensis and Leishmania major. J Microb Biochem Technol. 2014;6(2):54–62.
   Google Scholar
• Fairlie WD, Spurck TP, McCoubrie JE, et al. Inhibition of malaria parasite development by a cyclic peptide that targets the vital parasite protein SERA5. Infect Immun. 2008;76(9):4332–4344.
   PubMed Web of Science ®Google Scholar
• Gardiner DL, Trenholme KR, Skinner-Adams TS, et al. Overexpression of leucyl aminopeptidase in Plasmodium falciparum parasites. Target for the antimalarial activity of bestatin. J Biol Chem. 2006;281(3):1741–1745.
   PubMed Web of Science ®Google Scholar
• Triglia T, Healer J, Caruana SR, et al. Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Mol Microbiol. 2000;38(4):706–718.
   PubMed Web of Science ®Google Scholar
• Ilvie O, Franetich JF, Charrin S, et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J Biol Chem. 2004;279(10):9490–9496.
   PubMed Web of Science ®Google Scholar
• Proellocks NI, Kovacevic S, Ferguson DJ, et al. Plasmodium falciparum Pf34, a novel GPI-anchored rhoptry protein found in detergent-resistant microdomains. Int J Parasitol. 2007;37(11):1233–1241.
   PubMed Web of Science ®Google Scholar
• Arévalo-Pinzón G, Curtidor H, Vanegas M, et al. Conserved high activity binding peptides from the Plasmodium falciparum Pf34 rhoptry protein inhibit merozoites in vitro invasion of red blood cells. Peptides. 2010;31(11):1987–1994.
   PubMed Web of Science ®Google Scholar
• Yin LM, Edwards MA, Li J, et al. Roles of hydrophobicity and charge distribution of cationic antimicrobial peptides in peptide-membrane interactions. J Biol Chem. 2012;287(10):7738–7745.
   PubMed Web of Science ®Google Scholar
• Méndez-Samperio P. Role of antimicrobial peptides in host defense against mycobacterial infections. Peptides. 2008;29(10):1836–1841.
   PubMed Web of Science ®Google Scholar
• Seo MD, Won HS, Kim JH, et al. Antimicrobial peptides for therapeutic applications: a review. Molecules. 2012;17(10):12276–12286.
   PubMed Web of Science ®Google Scholar
• Ramón-García S, Mikut R, Ng C, et al. Targeting Mycobacterium tuberculosis and other microbial pathogens using improved synthetic antibacterial peptides. Antimicrob Agents Chemother. 2013;57(5):2295–2303.
   PubMed Web of Science ®Google Scholar
• Lan Y, Lam JT, Siu GK, et al. Cationic amphipathic D-enantiomeric antimicrobial peptides with in vitro and ex vivo activity against drug-resistant Mycobacterium tuberculosis. Tuberculosis (Edinb). 2014;94(6):678–689.
   PubMed Web of Science ®Google Scholar
• Vermeer LS, Lan Y, Abbate V, et al. Conformational flexibility determines selectivity and antibacterial, antiplasmodial, and anticancer potency of cationic α-helical peptides. J Biol Chem. 2012;287(41):34120–34133.
   PubMed Web of Science ®Google Scholar
• Rivas-Santiago B, Cervantes-Villagrana A, Sada E, et al. Expression of beta defensin 2 in experimental pulmonary tuberculosis: tentative approach for vaccine development. Arch Med Res. 2012;43(4):324–328.
   PubMed Web of Science ®Google Scholar
• Carroll J, Draper LA, O'Connor PM, et al. Comparison of the activities of the lantibiotics nisin and lacticin 3147 against clinically significant mycobacteria. Int J Antimicrob Agents. 2010;36(2):132–136.
   PubMed Web of Science ®Google Scholar
• Jonge MI, Pehau-Arnaudet G, Fretz MM, et al. ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. J Bacteriol. 2007;189(16):6028–6034.
   PubMed Web of Science ®Google Scholar
• Volkman HE, Clay H, Beery D, et al. Tuberculous granuloma formation is enhanced by a mycobacterium virulence determinant. PLoS Biol. 2004;2(11):e367.
   PubMed Web of Science ®Google Scholar
• Samuchiwal SK, Tousif S, Singh DK, et al. A peptide fragment from the human COX3 protein disrupts association of Mycobacterium tuberculosis virulence proteins ESAT-6 and CFP10, inhibits mycobacterial growth and mounts protective immune response. BMC Infect Dis. 2014;14:355.
   PubMed Web of Science ®Google Scholar
• Doi T, Yamada H, Yajima T, et al. H2-M3-restricted CD8+ T cells induced by peptide-pulsed dendritic cells confer protection against Mycobacterium tuberculosis. J Immunol. 2007;178(6):3806–3813.
   PubMed Web of Science ®Google Scholar
• Lauvau G, Pamer EG. CD8 T cell detection of bacterial infection: sniffing for formyl peptides derived from Mycobacterium tuberculosis. J Exp Med. 2001;193(10):F35–F39.
   PubMed Web of Science ®Google Scholar
• Mir SA, Sharma S. Immunotherapeutic potential of N-formylated peptides of ESAT-6 and glutamine synthetase in experimental tuberculosis. Int Immunopharmacol. 2014;18(2):298–303.
   PubMed Web of Science ®Google Scholar
• Kopian T, Kandror O, Tsu C, et al. Cleavage specificity of Mycobacterium tuberculosis ClpP1P2 protease and identification of novel peptide substrates and boronate inhibitors with anti-bacterial activity. J Biol Chem. 2015;290(17):11008–11020.
   PubMed Web of Science ®Google Scholar
• Famulla K, Sass P, Malik I, et al. Acyldepsipeptide antibiotics kill mycobacteria by preventing the physiological functions of the ClpP1P2 protease. Mol Microbiol. 2016;101(2):194–209.
   PubMed Web of Science ®Google Scholar
• Brötz-Oesterhelt H, Beyer D, Kroll HP, et al. Dysregulation of bacterial proteolytic machinery by a new class of antibiotics. Nat Med. 2005;11(10):1082–1087.
   PubMed Web of Science ®Google Scholar
• Hinzen B, Raddatz S, Paulsen H, et al. Medicinal chemistry optimization of acyldepsipeptides of the enopeptin class antibiotics. ChemMedChem. 2006;1(7):689–693.
   PubMed Web of Science ®Google Scholar
• Gavrish E, Sit CS, Cao S, et al. Lassomycin, a ribosomally synthesized cyclic peptide, kills Mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol. 2014;21(4):509–518.
   PubMedGoogle Scholar
• Gao W, Kim JY, Anderson JR, et al. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother. 2015;59(2):880–889.
   PubMed Web of Science ®Google Scholar
• Masood MM, Pillalamarri VK, Irfan M, Aneja B, et al. Diketo acids and their amino acid/dipeptidicanalogues as promising scaffolds for the development of bacterial methionine aminopeptidase inhibitors. RSC Adv. 2015;5(43):34173–34183.
   Web of Science ®Google Scholar
• Graz CJ, Grant GD, Brauns SC, et al. Cyclic dipeptides in the induction of maturation for cancer therapy. J Pharm Pharmacol. 2000;52(1):75–82.
   PubMed Web of Science ®Google Scholar
• Brezden A, Mohamed MF, Nepal M, et al. Correction to "dual targeting of intracellular pathogenic bacteria with a cleavable conjugate of kanamycin and an antibacterial cell-penetrating peptide". J Am Chem Soc. 2018;140(40):13125–13126.
   PubMed Web of Science ®Google Scholar
• Rhaiem RB, Houimel M. Targeting Leishmania major parasite with peptides derived from a combinatorial phage display library. Acta Trop. 2016;159:11–19.
   PubMed Web of Science ®Google Scholar